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Abstract (197/200) 
 
Objective: To synthesize the evidence across longitudinal studies comparing survival in dementia 
with Lewy bodies (DLB) and Alzheimer’s disease (AD). 
 
Methods: We conducted a systematic review and meta-analysis of studies comparing survival in 
clinically diagnosed DLB to AD. Longitudinal cohort studies were identified through a systematic 
search of major electronic databases from inception to May 2018.  A random effects meta-analysis 
was performed to calculate survival time and relative risk of death.   
 
Results: Overall, 11 studies were identified including 22,952 patients with dementia: 2,029 with DLB 
(mean diagnosis age 76.3; 47% female) compared with 20,923 with AD (mean diagnosis age 77.2; 
65.1% female). Average survival time in DLB from diagnosis was 4.11 years (SD ±4.10) and in AD 5.66 
(SD ±5.32) years, equating to a 1.60 (95% CI: -2.44 to -0.77) years shorter in DLB (p<0.01). Relative 
risk of death was increased by 1.35 (95%CI: 1.17-1.55) in DLB compared to AD (p<0.01). Differences 
in survival were not explained by follow-up time, age at diagnosis, gender, or cognitive score.  
 
Conclusions: There is consistent evidence for higher and earlier mortality in DLB compared to AD. 
This is important for all stakeholders and underlines the importance of expanding research into DLB.  
 
Key words: Dementia; Lewy bodies; Alzheimer’s disease; mortality 
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Introduction 
 
Dementia with Lewy bodies (DLB) is the second most common form of neurodegenerative dementia, 
accounting for up to a quarter of all diagnosed dementia cases (Vann Jones and O'Brien, 2014) and is 
estimated to be present in 1% of older adults (Ballard et al., 2013). Compared to Alzheimer’s disease 
(AD), DLB has been reported to have a considerably poorer prognosis and is associated with higher 
caregiver burden, higher costs of care, as well as increased rates of admission to general hospitals 
and residential care (Mueller et al., 2017a; Mueller et al., 2018). 
 
Survival in DLB has been a matter of considerable clinical and academic debate (Mueller et al., 
2017a). Initial post-mortem studies suggested a rapid mortality with survival times of less than two 
years (McKeith et al., 1992), but a later meta-analysis of neuropathologically confirmed cases of DLB 
published over 20 years ago suggested a longer mean survival time after diagnosis of 6.1 years 
(Cercy and Bylsma, 1997). Autopsy studies, which have provided most of the initial evidence, are 
prone to recruit biased cohorts, as post-mortems are usually carried out in selected samples of 
younger patients with uncertain diagnoses and atypical features (Walker et al., 2000). The advent of 
operationalized clinical criteria for DLB diagnosis (McKeith et al., 1996) paved the way for larger 
scale cohort studies to better understand prognosis and survival. Greater awareness amongst 
clinicians, further revisions of the diagnostic criteria (McKeith et al., 2017), the inclusion of DLB in 
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (American 
Psychiatric Association, 2013), and the increased use of naturalistic data from electronic health 
records (Price et al., 2017) has led to an expanding number of publications on survival in DLB. The 
majority of observational studies, but not all,  report shorter survival in DLB than AD (Mueller et al., 
2017a).  However, to the best of our knowledge, no systematic review or meta-analysis has 
synthesised this growing body of knowledge to describe and compare survival times from diagnosis.  
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Given the importance of understanding the prognosis of the DLB for patients, their families and 
service planners, we conducted a systematic review and meta-analysis of observational studies to 
determine survival times from diagnosis and differences between DLB and AD and relative risk of 
mortality (primary aim) and assessed via meta-regression which factors might account for these 
differences (secondary aim). 
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Methods 
 
This systematic review was conducted according to the Strengthening the Reporting of 
Observational Studies in Epidemiology [STROBE] criteria and the recommendations in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] statement (Liberati et al., 
2009; Wells G et al., 2012). 
 
Search strategy 
Two investigators (PS, NV) independently searched major databases (Pubmed, Medline, Scopus, 
Embase) without language restrictions, from inception until 01st May 2018. In Pubmed, the following 
controlled vocabulary terms and keywords were considered: (dementia lewy body or Lewy body OR 
Lewy bodies OR Lewy OR DLB OR LBD) and (mortality or death or survival). Similar searches were run 
in the other databases. Any inconsistencies were resolved by consensus with a third Author (CM).  
The reference lists of the articles included in the analysis were hand-searched to identify additional, 
potentially relevant publications. Conference abstracts were also considered. Authors were 
contacted at least two times in 1 month for obtaining additional information if needed.  
 
Study selection 
Two authors selected longitudinal cohort studies that reported survival time from dementia 
diagnosis (expressed in years) or in equivalents (e.g. months) in studies comparing people with DLB 
and AD.   
 
Inclusion/exclusion criteria  
We only considered studies that: (1) had a baseline and follow-up evaluation; (2) included patients 
with DLB, accepting all diagnostic criteria available (3) included a control group having a diagnosis of 
AD (accepting all diagnostic criteria available) (4) reported data on survival/mortality parameters, 
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expressed in years (from diagnosis of these conditions to death).  Studies were excluded if they: (1) 
did not include patients with DLB; (2) conducted in vitro and on animal models; (3) were conducted 
in selected samples of autopsy cases; (4) evaluated co-morbid AD pathology in patients with DLB; (5) 
compared AD to the Lewy body variant of AD, or (6) were reviews, book chapters and single case 
reports.  
 
Data extraction 
Two authors (PS, NV) independently extracted data from the selected studies in a standardized 
Microsoft Excel spreadsheet. Any disagreement was resolved with a third author (BS).  The following 
information was extracted: 1) characteristics of the study population (e.g. sample size, 
demographics, setting, country in which the study was performed); 2) mean age, mean education 
year, percentage of females and baseline mean mini-mental state examination (MMSE) at the 
diagnosis; 3) diagnostic criteria of DLB and AD; 4) average age at diagnosis; 5) all data about survival. 
We planned to extract additional data (e.g. those regarding neuropsychiatric symptoms, disability, 
average age at the onset of symptoms), but since they were present in less than 4 studies (the 
minimum for running a meta-regression analysis), we did not include these data.  
 
Assessment of study quality 
Two independent reviewers (PS, NV) assessed the quality of studies, with a third available to resolve 
any discrepancies (BS). The Newcastle-Ottawa Scale (NOS) was used to assess study quality, which 
assigns a maximum of 9 points based on three quality parameters: selection, comparability, and 
outcome (Luchini, 2017; Wells G et al., 2012).  Higher scores indicate better methodological quality.  
 
Outcomes 
The primary outcomes were survival data including mean survival time from diagnosis to death in 
DLB and AD. If expressed in other forms (e.g. median survival time, interquartile range survival time) 
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these estimates were transformed in means and standard deviations (SDs). If the SD was not 
reported and was not possible to calculate from the data available in the full-text, a pooled SD was 
calculated, in agreement with the Cochrane guidelines (Higgins and Green, 2008). We further 
estimated the risk of death during the follow-up period between DLB and AD groups and performed 
meta-regression analyses to test whether differences in mean age and MMSE at diagnosis, follow-up 
time and percentage of females explained outcome differences between the studied cohorts.   
 
Statistical analysis 
The meta-analysis was performed using the Comprehensive Meta-Analysis 2.0 (CMA) software.  
The difference, in mean, of the years survived in DLB group and in the AD group was reported 
through a mean difference (MD) with the correspondent 95% confidence intervals (CIs). The random 
effects model was used to account for anticipated between-study heterogeneity (DerSimonian and 
Laird, 1986). This was assessed using the Chi-squared and I-squared statistics, assuming that a 
p<0.10 for the former and a value ≥50% for the latter were indications of significant heterogeneity 
(Higgins and Thompson, 2002). For the primary outcome, whenever significant heterogeneity 
existed and ≥4 studies were available, a meta-regression analysis was performed examining the 
following pre-specified moderators: continent (categorized as Europe vs. America/Oceania); criteria 
used for DLB diagnosis (McKeith, 1992; McKeith, 1996; McKeith, 2005 or DSM-IV); year of 
publication (2000-2006, 2007-2012; 2013-2018); follow-up years (as continuous). Publication bias 
was assessed by visually inspecting funnel plots and using the Egger bias test (Egger et al., 1997). 
Finally, to account for publication bias, we used the trim-and-fill method, which adjusts for the 
potential effect of unpublished (imputed) studies (Duval and Tweedie, 2000).  
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Results 
The search identified 2,371 non-duplicated potentially eligible studies. After excluding 2,316 papers 
at title and abstract review, 55 full-text articles were examined, 11 of which  (Bostrom et al., 2009; 
Connors et al., 2016; Garcia-Ptacek et al., 2016; Koedam et al., 2008; Magierski et al., 2010; Mueller 
et al., 2018; Oesterhus et al., 2014; Price et al., 2017; Stubendorff et al., 2011; Walker et al., 2000; 
Williams et al., 2006) were finally included in the systematic review and meta-analysis (Figure 1). 
Additional or updated information was kindly provided by the authors of three of the studies 
(Garcia-Ptacek et al., 2016; Mueller et al., 2018; Oesterhus et al., 2014). 
 
General characteristics 
The 11 studies followed-up a total of 22,952 patients with dementia (2,029 with DLB compared with 
20,923 with AD) for a median of 5.02 years (Table 1). Nine studies were conducted in Europe (10; 
=81.8%). The quality of the studies was generally sufficient (median NOS=7, range: 4-9) and the most 
common potential source of bias was short follow-up periods and limited inclusion of possible 
confounders in the final analyses (see Supplementary Table 1). 
 
As reported in Table 1, the criteria suggested by McKeith, 2005 (McKeith et al., 2005) were the most 
commonly used for the diagnosis of DLB (4 studies; =36.3%). The 2,029 participants with DLB had a 
mean age of 76.3 (SD±7.0) years at the diagnosis and they were more frequently males (52.6%). 
They had a mean MMSE score of 21.1 (±5.1) at diagnosis. Of the comparison group with AD 
(N=20,923) the mean age was 77.2 (±8.0) years, most were female (65.0%) and mean MMSE score at 
diagnosis was 20.2 (±4.9).   
 
Overall, patients with DLB were younger at the time of diagnosis at a level close to statistical 
significance (p=0.08) than patients with AD, and a higher proportion were male (p<0.01). Mean 
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MMSE at diagnosis was slightly higher in patients with DLB, but this difference was not statistically 
significant (p=0.11). 
 
Differences in survival years between DLB and AD  
Figure 2 summarizes the differences in survival years between DLB and AD cohorts. Of the 11 
included studies, 7 reported significantly shorter survival in DLB than in AD, while the other 4 studies 
did not detect any statistically significant difference.  Mean survival time after diagnosis was 4.11 
(±4.10) years in people with DLB compared to 5.66 (±5.32) years in patients with AD. Hence survival 
was 1.60 years shorter in patients with DLB than in patients with AD (95% CI: -2.44 to -0.77 years; 
p<0.01), although between-study heterogeneity was high (I2=99%). The Egger’s test did not indicate 
significant publication bias (Egger’s test: -2.61 ± 2.59; p=0.33) and the trim and fill analysis did not 
meaningfully alter our findings. The fail-safe number for this outcome was high, needing 917 studies 
to nullify this finding. For those who died, the mean age at death was 80.8 (±7.0) for DLB and 83.7 
(±7.2) for AD (p=0.01). 
 
Seven studies (Bostrom et al., 2009; Connors et al., 2016; Garcia-Ptacek et al., 2016; Koedam et al., 
2008; Mueller et al., 2018; Oesterhus et al., 2014; Price et al., 2017) reported on the percentages of 
patients who died in the follow-up period. As shown in Figure 3, in the DLB cohort 780/1,838 
(42.4%) patients died during follow-up compared to 6,704/20,446 (32.8%) in the AD cohort. These 
estimates indicate a significantly higher risk of mortality in people with DLB compared to AD (relative 
risk =1.35; 95%CI: 1.17-1.55; p<0.01; I2=80%).  This outcome was also not apparently influenced by 
publication bias (Egger’s test: -0.20 ± 2.05; p=0.92) and the fail-safe number was 162.  
 
Meta-regression and sensitivity analyses 
Since our primary outcome had a high heterogeneity (I2=99%), we investigated potential factors 
underpinning this using meta-regression and sensitivity analyses. Supplementary Table 2 shows the 
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data on survival years stratified by continent, DLB diagnostic criteria applied (see Supplementary 
Table 3) and period of publication. Higher survival differences were observed in studies from outside 
Europe, and lower differences in older studies, but no significant interaction by stratum (p>0.05) was 
detected in any of the three categories.  
Meta-regression analyses reported in Supplementary Table 4 further demonstrate that none of the 
available moderators (i.e. follow-up period, differences in mean age, in mean MMSE, or in 
percentage of females) explained differences in survival time between AD and DLB.  
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Discussion 
This meta-analysis of 11 longitudinal studies including more than 2,000 people with a clinical 
diagnosis of DLB demonstrated that patients with DLB have a significantly shorter survival from 
dementia diagnosis than patients with AD. Survival time was almost 20 months shorter in patients 
with DLB and their average survival time was 4.1 years. Relative risk of death was 1.35 higher in DLB 
compared to AD, and although no significant difference was detected in age at diagnosis, patients 
with DLB had a significant lower age at death. Neither gender difference, age at diagnosis, nor 
MMSE scores explained differences in survival time between DLB and AD.  
 
Dementia is associated with a shortened life expectancy (Brodaty et al., 2012) and is increasingly 
recognised as a progressive, life-limiting condition without curative treatments, leading to a growing 
focus on advanced care planning (Perera et al., 2016; van der Steen et al., 2014). With the expected 
rise in people affected with dementia (Prince et al., 2013), giving indicators for prognosis, specifically 
survival, is of considerable interest both for patients, their families, as well as providers of health 
and social care services, with the aim to enable suitable support through the various stages of the 
illness (Todd et al., 2013). Several risk factors for mortality have been evaluated in patients with 
Alzheimer’s disease and all-cause dementia (Brodaty et al., 2012; Todd et al., 2013) but only recently 
there has been enquiry into non-Alzheimer’s dementias such as DLB.  DLB has been found to be 
associated with accelerated cognitive decline, higher rates of hospitalisation and residential care, 
higher health care costs and lower quality of life (Mueller et al., 2017a; Mueller et al., 2018). Our 
results demonstrate that survival in DLB in clinically diagnosed samples is not as poor as expected 
from early autopsy studies (McKeith et al., 1992), although is significantly lower than in patients with 
AD.  
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Although the available data only allows a coarse comparison, demographic characteristics and 
MMSE scores in our AD cohort (age at diagnosis 77 years; 65% female; mean MMSE 20) were similar 
to what is reported in larger samples of patients with Alzheimer’s disease.  For instance the data 
with AD are broadly comparable with  data from more than 26,000 patients diagnosed in Swedish 
memory clinics (age at diagnosis 80 years; 62% female; mean MMSE 21) (Cermakova et al., 2017) 
suggesting representability of our sample.  
 
A number of factors might explain the increased mortality risk in DLB compared to AD. Previous 
literature suggested that male gender could be identified as risk factor for mortality in dementia 
(Brodaty et al., 2012). Although this has not been replicated in all prevalence studies (Vann Jones 
and O'Brien, 2014), DLB has been associated with a male preponderance both in autopsy studies 
(Klatka et al., 1996) and clinical samples (Kane et al., 2018). Our data confirms the latter by 
demonstrating a significantly higher percentage of males on meta-analysis of DLB cohorts. However, 
when compared to AD group, our meta-regression analysis did not suggest a role of differences in 
gender between the groups in explaining shorter time survival observed in DLB compared to AD 
patients. We can argue that, in agreement with the literature reporting a higher risk of death in 
older male subjects compared to females (Xu et al., 2010), also DLB males die more frequently than 
women, but this factor is not significant in explaining the differences in survival time between DLB 
and AD.  
Although the difference only amounted to a trend (p<0.1), DLB patients were also diagnosed at a 
slightly younger age. With age not explaining survival differences on meta-regression, despite being 
as strong risk factor for mortality (Todd et al., 2013), patients with DLB might be at a risk of an higher 
loss of life expectancy compared to those with other forms of dementia. This concurs with one 
Norwegian study finding that patients with DLB had a higher standardized mortality ratio compared 
to the general population than patients with AD (2.6 vs. 1.5) (Oesterhus et al., 2014) and is 
underlined by a significantly younger age of death in DLB than AD (81 vs. 84 years).   
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Dementia disease severity can be assessed from a global, functional or cognitive perspective. The 
only measure available for the included studies was MMSE, which is not consistently associated with 
mortality risk in dementia (Todd et al., 2013) and might be too coarse an instrument to assess 
severity in DLB (Mueller et al., 2018). On meta-analysis we did not find differences in MMSE at 
baseline between DLB and AD cohorts, underlining the need for more in-depth testing and 
description of domains of cognitive decline between the conditions.  
Although we cannot directly infer this from our data, other features of DLB and associated 
synucleinopathies, as motor, neuropsychiatric or autonomic symptoms, might contribute to the 
increased mortality risk. In patients with Alzheimer’s disease, Parkinson-related symptoms as 
extrapyramidal signs, gait and postural instabilities and falls are related to increased mortality 
(Larson et al., 2004; Stern et al., 1997). Orthostatic hypotension is a specific risk factor for falls in 
patients with dementia (Allan et al., 2009) and is a predictor of mortality in DLB (Stubendorff et al., 
2012). In addition to orthostatic hypotension, the effects of cardiovascular autonomic dysfunction, 
including neurocardiovascular instability, carotid sinus syndrome and abnormal sinus 
bradyarrhythmia, may cause a decrease in blood pressure negatively affect disease progression and 
survival of patients with DLB (Fanciulli et al., 2013; Kenny et al., 2002; Kenny et al., 2004). It is 
further possible that the neurodegenerative process in the synucleinopathy DLB is more rapid than 
in Alzheimer’s disease, and a cell-to-cell alpha-synuclein spread has been hypothesized (George et 
al., 2013). Further AD-like pathological changes such as tau-inclusions and beta-amyloid are also 
likely to be present to some degree in DLB, and synergistic interactions between the three proteins 
have been suggested yielding a worse prognosis (Irwin et al., 2013).  
 
Neuropsychiatric symptoms are more common in DLB than AD (Mueller et al., 2018), and in patients 
diagnosed with dementia these are independently associated with mortality, in particular the DLB 
core feature of visual hallucinations and the supportive feature of depression (Mehta et al., 2003; 
Okura et al., 2011; Scarmeas et al., 2005). Fluctuating cognition is a feature common to both DLB 
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and delirium (Gore et al., 2015). As delirium frequently occurs in the months and weeks prior to a 
DLB diagnosis being established a delirium onset type of DLB has been postulated, whereby clinical 
misclassification being an alternative explanation (FitzGerald et al., 2018; McKeith et al., 2016; 
Morandi et al., 2017). Delirium is associated with increased mortality in older adults (Eeles et al., 
2010) and this hazard might be increased in people diagnosed with delirium in the absence of a prior 
diagnosis of dementia, typical for DLB (Ward et al., 2015). 
 
More than these features themselves, mortality risk in DLB may be further increased because of the 
medications prescribed to address them. The known increased mortality risk related to antipsychotic 
prescribing (e.g. for hallucinations or delirium) in people with dementia (Tampi et al., 2016) may be 
further amplified in those with DLB due to the pathognomonic feature of neuroleptic sensitivity 
(McKeith et al., 2005). However, although the majority of included studies report a higher 
proportion of these medications prescribed in DLB, antipsychotic prescription didn’t emerge as 
significant modifier of survival differences in one study (Price et al., 2017). Although only 
demonstrated in Alzheimer’s disease (Mueller et al., 2017b) and probably lower than antipsychotic 
risks (Maust et al., 2015), prescription of antidepressants in dementia might be associated with an 
increased mortality risk in patients with dementia.  
Lastly, survival benefits of acetylcholinesterase inhibitors are well-demonstrated in AD (Mueller et 
al., 2017c) and these medications are in DLB associated with later transition to residential care and 
lower health care costs (Mueller et al., 2017a). Although no head-to-head comparisons are available, 
two studies reported level of antidementia drug use to be at a similar level in both cohorts (Price et 
al., 2017; Stubendorff et al., 2011) indicating that neither cohort is deprived of the benefits of these 
medications.   
 
 
 
16 
 
Limitations: 
Although our findings provide clinicians with helpful pointers to discuss prognosis with patients and 
carers, several caveats in assessing survival in patients with dementia need to be acknowledged.  
First, we collated reported survival from the time of dementia diagnosis, as this is the point in time 
when questions about prognosis often arise. This is an imprecise timepoint as it depends on various 
patient, physician and service related factors, as cultural background, readiness to refer to 
secondary service, or availability of diagnostic services which might change over time (Todd et al., 
2013).  Inaccuracies arise in particular in DLB since caregivers report that the diagnosis is established 
after more than one year in half of the cases, and more than three quarters of cases receiving a 
different diagnosis initially (Galvin et al., 2010). However, this appears superior to symptom onset, 
as this is determined by recall bias,  and variations in ability and threshold to recognize symptoms 
(Brodaty et al., 2012). 
Second, the majority of studies did not neuropathologically confirm the dementia subtype diagnosis. 
However, although not as accurate as neuropathologically confirmed diagnoses, the clinical 
diagnoses applied in the included studies are more likely to reflect the reality of day-to-day practice. 
Diagnostic criteria have evolved since the first consensus guideline were established in 1996 
(McKeith et al., 1996), with the 2005 revision (McKeith et al., 2005) increasing detection by one 
quarter (Aarsland et al., 2008). A recent meta-analysis (Rizzo et al., 2018) demonstrated that the 
diagnostic criteria have become more sensitive, but less specific, over time, which appears desirable 
given that DLB remains underdiagnosed in clinical practice (Kane et al., 2018).  
A third limitation of our study is high heterogeneity, which is common in meta analyses of 
observational data.  We attempted to address this by utilizing a random effects meta-analysis and 
through meta-regression analyses.  However, we were unable to explain large portions of the 
variability we encountered.  To further reduce heterogeneity, we only included studies which 
followed newly-diagnosed patients and excluded prevalence studies or studies solely including 
patients on the basis of available autopsy samples. Heterogeneity was not explained by the 
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continent where the study was conducted, the diagnostic criteria used for DLB, the time period of 
publication, follow-up time available or patient characteristics. The most important potential 
explanation of heterogeneity may be the above-mentioned variation in presentation in the patient 
group itself, as well as variations in diagnostic practice, both regionally and over time (Kane et al., 
2018; McKeith et al., 2016; Rizzo et al., 2018). One scenario is the so-called Lewy-body variant of 
Alzheimer’s disease, which relies on the presence of neuropathological criteria for AD and the 
additional presence of Lewy bodies. Under these conditions clinicians often do not make a diagnosis 
of DLB (McKeith et al., 2016; Thomas et al., 2018). However, when survival between the Lewy-body 
variant of AD was compared with pure AD in several post-mortem studies (Chung et al., 2015; Lopez 
et al., 2000; Olichney et al., 1998), only one out of four studies (Olichney et al., 1998) reported worse 
survival of Lewy-body variant AD. It has been postulated that Lewy-body pathology might be a 
feature of late-stage Alzheimer’s disease, as 45% of 22 neuropathologically confirmed cases of AD 
had co-existing Lewy bodies (Toledo et al., 2013). In contrast, studies evaluating the other scenario 
of mixed pathologies, the presence of AD pathology in patients with clinically diagnosed (Bostrom et 
al., 2009; Graff-Radford et al., 2016; Lemstra et al., 2017) and autopsy confirmed (Irwin et al., 2017; 
Jellinger et al., 2007) DLB have consistently demonstrated that co-morbid AD pathology increases 
mortality risk.  We measured heterogeneity of the effect sizes using the I2 statistic as recommended 
by the Cochrane hand book (REF).  However, it is important to also consider that the I2 metric may 
have some limitations when there are under than 20 studies (Langan et al., 2015).  
Fourth, data available only allowed comparison of DLB to AD, with survival time for AD (5.7 years) 
being within the range previously reported  (3.2 to 6.6 years) (Todd et al., 2013). Despite AD being 
the far most common type, future studies could attempt to elucidate survival differences in other 
dementia-causing disorders.  
Fifth, we didn’t have sufficient information to include ApoE4 status into the meta-analysis. However, 
a recent study in Alzheimer’s disease has not implicated ApoE4 in survival (Rhodius-Meester et al., 
2018) and the one included study (Williams et al., 2006) applying ApoE4 as a potential effector of 
18 
 
mortality differences between AD and DLB only detected a statistically significant effect from 
disease onset, not diagnosis, underlining its role as risk factor.   
Lastly, changes in practice over time might affect survival, which could have improved over the 
studied period through greater awareness of public health measures (Livingston et al., 2017) and the 
availability of cholinesterase inhibitors which have been associated with survival benefits (Mueller et 
al., 2017c). However, period of study did not emerge as a moderator of the observed association on 
meta-regression.  
 
Conclusions: 
Survival time after diagnosis of DLB is of growing clinical and research interest. A review conducted 
eight years ago (Brodaty et al., 2012) included less than 200 cases of DLB, and we are now able to 
report more than ten times the combined sample size. Although heterogeneity is pronounced in 
mortality and Lewy body disorder research, our findings suggest that patients diagnosed with DLB 
have shorter survival from dementia diagnosis than patients with AD. A mean survival time of 4.1 
years was concluded from this review, but mean survival times from diagnosis in the included 
studies ranged from 1.9 to 6.3 years, so there is clearly substantial heterogeneity which limits what 
can be reasonably communicated to individuals at this stage.  Higher mortality suggests a higher 
likelihood of morbidity and dependency, and while the demonstrating a shorter survival in DLB 
compared to AD is important for patients, their families and policy makers, important next steps are 
examining how this reduced life expectancy determines time spent at different levels of morbidity 
and the identification of specific risk factors of early mortality in this under-researched population.  
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Table 1.  Descriptive characteristics of the studies included.  
    DLB AD 
Author (year) Country Follow-up (years) 
 
Diagnostic 
criteria  N Age at diagnosis (SD) 
Survival 
from 
diagnosis 
to death 
(y; SD) 
Female (%) MMSE at diagnosis (SD) N Age at diagnosis (SD) 
Survival 
from 
diagnosis 
to death 
(y) 
Female (%) MMSE at diagnosis (SD) 
Boström  F 
et al., 2009  
Sweden 7 McKeith criteria,2005 47 
 
 
5.59 (5.7) 46.8 22.7 (5.3) 159 
 
 
7.02 
(7.16) 
 
75.5 20.2 (4.9) 
Connors M 
et al., 2016  
Australia 3 DSM-IV 16 75.1 (5.7) 
3.87 
(1.46) 25 23.8 (4.2) 521 
76.7 
(7.9) 
6.21 
(2.89) 51.2 21.1 (5.3) 
Garcia-
Ptacek et al., 
2016*  
Sweden 2,03 McKeith criteria,2005 1054 
76.52 
(7.06) 
 
2.06 
(1.31) 
39.7 21.41 (5.04) 9137 
77.58 
(8.27) 
 
2.29 
 (1.39) 
65.2 21.5 (5.01) 
Koedam EL 
et al., 2008 Netherlands 2,5 
McKeith 
criteria, 1996 52 
75 
(7) 
 
1.9 (1.6) 
33 22 (5) 589 
71 
(10) 
 
3.4 (2.2) 
57 20 (5) 
Magierski R 
et al., 2010  
Poland 8 McKeith criteria,1996 47 
76.6 
(4.4) 
6.3  
(0.4) 70.2 19.9 (4) 103 
78.1 
(4.9) 
8.3  
(0.4) 68 20.3 (3.1) 
Oesterhus R 
et al.,2014* 
  
Norway 6,7 McKeith criteria,2005 77 
76.6 
(7.3) 
 
4.52 48.1 23.3 (3.2) 111 
75.6 
(7.4) 
 
7.42 71.2 23.7 (2.3) 
Mueller C et 
al., 2018* UK 10 
McKeith 
criteria,2005$ 341 
78.6 
(9.5) 
3.44 
50.2 19.5 (6.4) 9707 
80.8 
(9.3) 
4.76 
 65.34 
18.8 
(6.4) 
Price A et al., 
2017 UK 8 
McKeith 
criteria,2005 251 
79.3 
(7.6) 
 
4.40 
(2.63) 
51.4 20.1 (5.5) 222 
80.2 
(8.8) 
 
 
6.99 
(7.05) 
62.6 20.6 (4.9) 
Stubendorff 
K et al., 2011 Sweden 5 
McKeith 
criteria, 1996 49 
75.8 
(6) 
4.7 (SE: 
1.30)± 45 
22 
(8-29) 79  
76 
(6.0) 
6.5 (SE: 
1.03) ± 73 
21 
(6-29) 
Walker Z et 
al., 2000  
UK 3 McKeith criteria, 1992 32 
75.8 
(NA) 
 
3.5 
(mean) 
71,8 16.7 (7.1) 43 
78.1 
(NA) 
 
3.1 
(mean) 
65.1 15.8 (7.6) 
Williams M et 
al., 2006 USA 
 McKeith 
criteria, 1996 63 
73.5 
(8.7) 
 
5.00 (SE: 
1.54) 
40.3  252 77.8 (9.5) 
 
62.3  
    6.30 
(SE: 
0.81) 
Total  Median =5.02 (range: 2-10) 
 
2029 
Mean= 
76.3 
(7.03) 
  
47.4 
Mean= 
21.1 
(4.7) 
20,923 
Mean= 
77.2 
(8.0) 
 
65.1 
Mean= 
20.3  
(4.9) 
 
 
* Updated  data acquired from author, $ 69 cases were examined according to McKeith criteria 2005, with a positive predictive value of 78% for 
DLB, ± only available for patients who died (80% in DLB group; 75% in AD group) 
Figure 1. PRISMA flow-chart 
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 Figure 2: Comparison of survival time from dementia diagnosis in DLB and AD 
 
 
 
 
 
Figure 3: Comparison of risk of death in DLB and AD 
 
Supplementary Table 1. Quality assessment with Newcastle-Ottawa Scale of the studies included in the systematic review. 
First author, 
publication year 
Representa
tiveness of 
the sample 
Sample 
size 
Non-
respond
ents 
Ascertainm
ent of the 
exposure 
(risk factor) 
† 
The study 
controls for 
the most 
important 
factor ††                                           
 
The study control 
for any additional 
factor††† 
 
Assessment of 
the outcome 
Statistical test 
Total 
quality 
scores 
Boström et al., 
2009 
* * * ** * * * * 9 
Connors et 
al,2016 
* - * - * - * * 5 
Garcia-Ptacek et 
al., 2016 * * * ** * * * * 9 
Hanyu et al., 
2009 * * * * - - * * 6 
Koedam et al., 
2008 * * * * * - * * 7 
Magierski et al., 
2010 * * * * * - * * 7 
Oesterhus et al., 
2014 * * * ** * * * * 9 
Mueller et al., 
2018 * * * * * * * * 8 
Price et al., 2017 * * * ** - - * * 7 
Stubendorff et 
al., 2011 * * * * - - * * 6 
Walker et al., 
2003 * * * * - - * * 6 
Williams et al., 
2006 * * * * * * * * 8 
          
† For this index, two stars were given if in Methods section DLB and AD were diagnosed according with McKeith 2005 criteria used for DLB; and ICD-10/DSM-IV/ National Institute on Aging-
Alzheimer’s Association for AD, respectively.  One star was given if McKeith 1992/1996 were used for DLB used. No star if other or no criteria. 
 †† For this index, one star was given if two confounding factors were evaluated.  
 ††† For this index, one star was given if additional factor was evaluated.  
 
 
Supplementary Table 2. Stratification for some potential confounders for the association 
between DLB and mortality (compared to AD).  
Moderator Strata Analysis details Mortality (years) 
Continent 
 
Europe 
 
 
 
 
Oceania/America 
 
 
 
 
 
Pooled estimate, MD (95%CI) 
P-value for estimate 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, MD (95%CI) 
P-value for estimate 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value * 
-1.54 (-2.44 to -0.64) 
0.001 
98 (<0.0001) 
9 
 
-2.19 (-3.51 to -0.88) 
0.001 
0 (0.59) 
2 
 
0.42 
DLB diagnostic 
criteria used 
McKeith, 2005± 
 
 
 
 
McKeith, 1996 
 
 
 
 
McKeith, 1992 
 
 
Pooled estimate, MD (95%CI) 
P-value for estimate 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, MD (95%CI) 
P-value for estimate 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, MD (95%CI) 
P-value for estimate 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value * 
-1.77 (-2.94 to -0.61) 
0.003 
93 (<0.0001) 
6 
 
-1.98 (-2.11 to -1.84) 
<0.0001 
0 (0.46) 
4 
 
0.40 (-1.81 to 2.61) 
0.72 
- 
1 
 
0.11 
Year of publication 2000 – 2006 
 
 
 
 
2007 – 2012 
 
 
 
 
2013 - 2018 
 
Pooled estimate, MD (95%CI) 
P-value for estimate 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, MD (95%CI) 
P-value for estimate 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, MD (95%CI) 
P-value for estimate 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value * 
-0.08 (-1.96 to 1.79) 
0.93 
0 (0.42) 
2 
 
-1.97 (-2.11 to -1.84) 
<0.0001 
0 (0.44) 
4 
 
-1.82 (-3.08 to -0.56) 
0.005 
95 (<0.0001) 
5 
 
0.14 
 
* P-value represents the interaction between strata. ± includes one study using DSM-IV 
Abbreviations: MD: mean differences; CI: confidence intervals.   
Supplementary Table 3. Diagnostic criteria for DLB applied in the included studies 
 Central feature Core features Suggestive features Diagnostic algorithm  
McKeith, 2005 
 
Dementia defined as progressive 
cognitive decline of sufficient 
magnitude to interfere with normal 
social or occupational function. 
o Fluctuating cognition with 
pronounced variations in 
attention and alertness. 
o Recurrent visual 
hallucinations that are 
typically well formed and 
detailed.  
o Spontaneous features of 
parkinsonism. 
 
o REM sleep behavior 
disorder.  
o Severe neuroleptic 
sensitivity. 
o Low dopamine 
transporter uptake in 
basal ganglia 
demonstrated by SPECT 
or PET imaging 
A diagnosis of dementia is 
essential. 
Two core features are 
sufficient for a diagnosis of 
probable DLB, one for 
possible DLB. 
If one core feature and at 
least one suggestive feature is 
present a diagnosis of DLB 
can be made.  In the absence 
of any core features, one or 
more suggestive features is 
sufficient for possible DLB.  
McKeith, 1995 
 
 
Progressive cognitive decline of 
sufficient magnitude to interfere 
with normal social or occupational 
function. 
 
o Fluctuating cognition with 
pronounced variations in 
attention and alertness. 
o Recurrent visual 
hallucinations that are 
typically well formed and 
detailed.  
o Spontaneous features of 
parkinsonism. 
 
 
Only supportive, but no 
suggestive features, in the 
criteria.   
The central feature is 
required.  
Two of the core features are 
essential for a diagnosis of 
probable DLB, and one is 
essential for possible DLB. 
McKeith, 1992 
 
Fluctuating cognitive impairment 
affecting both memory and 
higher cortical functions (such as 
language, visuospatial 
o Visual and/or auditory 
hallucinations which are 
usually accompanied by 
secondary paranoid 
delusions; 
 A fluctuation cognitive 
impairment which is 
persistent is essential. A 
diagnosis of senile dementia 
of Lewy body type can be 
ability, praxis or reasoning skills). 
The fluctuation is marked with the 
occurrence of both episodic 
confusion and lucid intervals, as in 
delirium, and is evident either on 
repeated 
tests of cognitive function or by 
variable performance in daily 
living skills. 
Despite the fluctuating pattern the 
clinical features persist over a long 
period of time (weeks or months) 
unlike delirium which rarely 
persists as long. 
o Mild spontaneous 
extrapyramidal features or 
neuroleptic 
sensitivity syndrome, i.e. 
exaggerated adverse 
responses to 
standard doses of neuroleptic 
medication; 
o Repeated unexplained falls 
and/or transient clouding or 
loss of consciousness. 
made if at least one of the 
core features is present  
 
  
 
Supplementary Table 4. Meta regression of potential moderators of survival differences 
between DLB and AD 
Moderator Number 
comparisons 
β 95% CI P value R² 
Follow-up 10 -0.15 -0.56 0.25 0.41 0 
Difference in mean 
age (DLB vs. AD) 
11 -0.02 -0.52 0.48 0.94 0 
Difference in 
percentage of females 
(DLB vs. AD) 
11 -0.05 -0.13 0.03 0.17 0 
Difference in mean 
MMSE (DLB vs. AD) 
11 0.33 -0.53 1.19 0.40 0 
 
Abbreviations: CI: confidence intervals.   
 
